Clinical Lung Cancer

Papers
(The H4-Index of Clinical Lung Cancer is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibito124
Correlation of PET-CT, Endobronchial Ultrasound Cytology and Surgical Biopsy in Patients with Non-Small Cell Lung Cancer Undergoing Curative Surgery93
Editorial Board66
Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.64
Comments on “Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma”59
Untapping the Prognostic Value of Patient-Generated Health Data in Locally Advanced Non-small Cell Lung Cancer51
Small Cell Lung Cancer With de novo BRAF V600E Mutation and Durable Response to Targeted Therapy: A Case Report44
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations43
Correspondence on SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies41
Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy35
Factors Influencing Refusal of Adjuvant Chemotherapy in Non–Small Cell Lung Carcinoma33
Adequate Number of Lymph Nodes Sampled May Determine Appropriate Surgical Modality for Early-Stage NSCLC: A Population-Based Real-World Study31
A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer29
Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular Characteristics29
Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy29
Transarterial Embolization for the Management of Emergent Hemoptysis in Patients With Primary and Metastatic Lung Tumors28
Genomic Profiling of Driver Gene Alterations in Patients With Non–Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients27
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status24
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non–Small-Cell Lung Cancer23
A National Survey of Surgeons Evaluating the Accuracy of Mediastinal Lymph Node Identification23
Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma23
Table of Contents23
Lung Cancer Patients’ and Caregivers’ Satisfaction With Multidisciplinary Versus Serial Care in a Community Healthcare Setting: A Prospective Comparative-Effectiveness Cohort Study23
Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview Study23
0.14440011978149